Form 4: Amicus Therapeutics Acquired by BioMarin

Director Michael Kelly reports the disposal of all Amicus Therapeutics equity holdings following the company's acquisition by BioMarin Pharmaceutical.

Summary

• Director Michael Aaron Kelly disposed of 72,468 shares of Amicus Therapeutics common stock at $14.50 per share.
• Multiple tranches of stock options totaling 229,347 shares were cancelled and converted into cash payments based on the $14.50 acquisition price.
• The transactions were executed on April 27, 2026, in connection with the completed merger with BioMarin Pharmaceutical Inc.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing documenting the final exit of an insider following a completed corporate acquisition.

Positives

• The acquisition by BioMarin provides liquidity to shareholders at a fixed price of $14.50 per share.
• All outstanding stock options held by the director were fully vested and converted into cash.

Negatives

• The director no longer holds any equity interest in Amicus Therapeutics following the completion of the merger.

Risks

• No ongoing risks as the issuer has been acquired and the reporting person has exited their position.

Future Outlook

The company has been acquired by BioMarin Pharmaceutical Inc.; no further independent guidance is provided.

Industry Context

StockSavvy.ai notes that this filing confirms the finalization of a significant M&A event in the biotechnology sector, reflecting ongoing consolidation trends where larger pharmaceutical entities acquire specialized firms to bolster their rare disease or specialty drug pipelines.

Comparison to Industry Standards

• The acquisition price of $14.50 represents the final exit valuation for the issuer's equity holders.
• The conversion of unvested options into cash upon change-of-control is standard practice in biotech M&A agreements.

Stakeholder Impact

• Shareholders receive cash consideration for their holdings.
• Director and officer equity interests are liquidated.

Next Steps

• Final delisting of Amicus Therapeutics common stock from public exchanges.

Key Dates

Keywords

Amicus Therapeutics, BioMarin, Merger, Acquisition, Form 4, Insider Transaction